These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31897805)

  • 1. Assessing Drug Release from Manipulated Abuse Deterrent Formulations.
    Feng X; Zidan A; Kamal NS; Xu X; Sun D; Walenga R; Boyce H; Cruz CN; Ashraf M
    AAPS PharmSciTech; 2020 Jan; 21(2):40. PubMed ID: 31897805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets.
    Meruva S; Rezaei L; Thool P; Donovan MD
    AAPS PharmSciTech; 2020 Oct; 21(7):270. PubMed ID: 33025237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies.
    Meng Z; Boyce HJ; Sun D; Kinjo M; Raofi S; Li T
    Pharm Res; 2021 Jul; 38(7):1263-1278. PubMed ID: 34128146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Assessment of Nasal Insufflation of Comminuted Drug Products Designed as Abuse Deterrent Using the Vertical Diffusion Cell.
    Boyce H; Smith D; Byrn S; Saluja B; Qu W; Gurvich VJ; Hoag SW
    AAPS PharmSciTech; 2018 May; 19(4):1744-1757. PubMed ID: 29582347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of basket mesh size on the hydrodynamics of a partially filled (500 mL) USP rotating basket dissolution testing Apparatus 1.
    Sirasitthichoke C; Patel S; Reuter KG; Hermans A; Bredael G; Armenante PM
    Int J Pharm; 2024 Jun; 658():124209. PubMed ID: 38718973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Approach for the Application of USP Apparatus 3 in Dissolution Tests: Case Studies of Three Antihypertensive Immediate-Release Tablets.
    Espíndola B; Bortolon FF; Pinto JMO; Pezzini BR; Stulzer HK
    AAPS PharmSciTech; 2018 Oct; 19(7):2866-2874. PubMed ID: 29934804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations.
    Rahman Z; Yang Y; Korang-Yeboah M; Siddiqui A; Xu X; Ashraf M; Khan MA
    Int J Pharm; 2016 Apr; 502(1-2):138-50. PubMed ID: 26911416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique.
    Kir F; Al-Sulaiti FK; Sahin S
    Eur J Pharm Sci; 2024 Mar; 194():106694. PubMed ID: 38191064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of excipients and curing process on the abuse deterrent properties of directly compressed tablets.
    Rahman Z; Zidan AS; Korang-Yeboah M; Yang Y; Siddiqui A; Shakleya D; Khan MA; Cruz C; Ashraf M
    Int J Pharm; 2017 Jan; 517(1-2):303-311. PubMed ID: 27956191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations.
    Wening K; Schwier S; Stahlberg HJ; Galia E
    J Opioid Manag; 2017; 13(6):473-484. PubMed ID: 29308593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate.
    Barakh Ali SF; Dharani S; Afrooz H; Mohamed EM; Cook P; Khan MA; Rahman Z
    AAPS PharmSciTech; 2020 Mar; 21(3):99. PubMed ID: 32133549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.
    Lu Z; Fassihi R
    AAPS PharmSciTech; 2017 Feb; 18(2):462-472. PubMed ID: 27106916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expedited Tablet Formulation Development of a Highly Soluble Carbamazepine Cocrystal Enabled by Precipitation Inhibition in Diffusion Layer.
    Yamashita H; Sun CC
    Pharm Res; 2019 Apr; 36(6):90. PubMed ID: 31016440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Evaluation of Dissolution Performance in a USP 2 Setup and Alternative Stirrers and Vessel Designs: A Systematic Computational Investigation.
    Salehi N; Al-Gousous J; Hens B; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2024 May; 21(5):2406-2414. PubMed ID: 38639477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpreting
    Rudd ND; Reibarkh M; Fang R; Mittal S; Walsh PL; Brunskill APJ; Forrest WP
    Mol Pharm; 2020 May; 17(5):1734-1747. PubMed ID: 32267708
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Medina-López R; Guillén-Moedano S; Hurtado M
    ADMET DMPK; 2020; 8(4):411-423. PubMed ID: 35300193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product.
    Qureshi SA; McGilveray IJ
    Eur J Pharm Sci; 1999 Feb; 7(3):249-58. PubMed ID: 9845813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of USP apparatus 3 for dissolution testing of immediate-release products.
    Yu LX; Wang JT; Hussain AS
    AAPS PharmSci; 2002; 4(1):E1. PubMed ID: 12049485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dissolution profiles for albendazole tablets using USP apparatus 2 and 4.
    Hurtado y de la Peña M; Vargas Alvarado Y; Domínguez-Ramírez AM; Cortés Arroyo AR
    Drug Dev Ind Pharm; 2003 Aug; 29(7):777-84. PubMed ID: 12906335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of Abuse-deterrent properties of PEO-based Abuse-deterrent formulation.
    Kibria G; Bandaranayake B; Zheng J; Lee S; Cruz C
    Int J Pharm; 2023 Jan; 631():122430. PubMed ID: 36493968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.